Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Is parathyroid hormone (1–84) a safe and effective treatment for postmenopausal osteoporosis?

Nature Clinical Practice Endocrinology & Metabolism volume 3, pages 746–747 (2007)Cite this article

boxed-textGreenspan SL et al. (2007) Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial. Ann Intern Med 146: 326–339

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Bone health and osteoporosis: a report of the Surgeon General (2004) [http://www.surgeongeneral.gov/library/bonehealth/content.html] (accessed 3 July 2007)

  2. Neer RM et al. (2001) Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441

    Article  CAS  Google Scholar 

  3. Inomata N et al. (1995) Characterization of a novel parathyroid hormone (PTH) receptor with specificity for the carboxyl-terminal region of PTH-(1–84). Endocrinology 136: 4732–4740

    Article  CAS  Google Scholar 

  4. Jolette J et al. (2006) Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1–84 in a 2-year study in Fischer 344 rats. Toxicol Pathol 34: 929–940

    Article  CAS  Google Scholar 

  5. Vahle JL et al. (2004) Bone neoplasms in F344 rats given teriparatide [rhPTH (1–34)] are dependent on duration of treatment and dose. Toxicol Pathol 32: 426–438

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Vicky Heath, Associate Editor, Nature Clinical Practice.

Author information

Author notes

  1. Endocrine Unit, Massachusetts General Hospital, 50 Blossom Street, THR-1051, Boston, MA 02114, USA bzleder@partners.org

Authors and Affiliations

  1. BZ Leder is a Clinical Investigator in the Endocrine Unit, Massachusetts General Hospital, Boston, MA, USA.,

    Benjamin Z Leder

Authors
  1. Benjamin Z Leder
    View author publications

    You can also search for this author in PubMed Google Scholar

Ethics declarations

Competing interests

BZ Leder is a consultant for Amgen, has received research support from AstraZeneca, and is a member of the Merck speaker's bureau.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leder, B. Is parathyroid hormone (1–84) a safe and effective treatment for postmenopausal osteoporosis?. Nat Rev Endocrinol 3, 746–747 (2007). https://doi.org/10.1038/ncpendmet0626

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpendmet0626

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing